10-K/A: Indoor Harvest Corp. Files Amended 10-K, Reports on Restructuring and Strategic Shift

Indoor Harvest Corp. has filed an amended annual report on Form 10-K, detailing its financial results for 2023 and outlining its strategic shift towards becoming a consolidation platform for plant-based industry companies.

Summary

• Indoor Harvest Corp. filed an amendment to its annual report on Form 10-K for the year ended December 31, 2023.
• The amendment includes updated financial statements, required certifications, and XBRL files.
• The company is repositioning itself as an integrated consolidation platform for plant-based industry companies, focusing on hemp, CBD, and related products.
• The company reported no revenue for both 2023 and 2022.
• Operating expenses decreased by 42% from $3,370,813 in 2022 to $1,967,414 in 2023, primarily due to a reduction in general and administrative expenses.
• The net loss for 2023 was $3,261,618, a slight improvement from the $3,363,597 loss in 2022.
• The company's cash balance decreased to $0 as of December 31, 2023, from $226,231 in 2022.
• The company had a working capital deficiency of $1,289,667 as of December 31, 2023.
• The company issued 412,513,972 shares of common stock in 2023 through private placements, raising $1,212,911.
• The company has 3,105,704,056 shares of common stock issued and outstanding as of December 31, 2023.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including no revenue, a depleted cash balance, and a working capital deficiency. While there are some positive aspects, such as cost management and a strategic shift, the overall financial situation and internal control weaknesses raise concerns.

Positives

• The company is actively restructuring and repositioning itself for future growth.
• Operating expenses have decreased significantly, indicating cost management efforts.
• The net loss has slightly decreased year-over-year.
• The company has secured funding through private placements, raising $1,212,911 in 2023.

Negatives

• The company has reported no revenue for the past two years.
• The company's cash balance has decreased to $0.
• The company has a significant working capital deficiency of $1,289,667.
• The company has incurred substantial losses and has an accumulated deficit.
• The company's internal controls over financial reporting were deemed ineffective as of December 31, 2023.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital and executing its business plan.
• The company faces risks related to the regulatory environment surrounding cannabis and hemp.
• The company's internal controls over financial reporting are not effective, which could lead to misstatements in financial reports.
• The company has a limited number of employees, which could impact its ability to execute its business strategy.
• The company's assets could be subject to forfeiture due to federal laws regarding cannabis.

Future Outlook

The company plans to focus on M&A and strategic partnerships to create shareholder value, while managing costs related to being a fully reporting company. The company will be working on branding and continuing to build its team in 2024, once it has its new plans funded.

Management Comments

• The company believes it is positioned to start executing its business strategy and leveraging the public company to create shareholder value.
• The recent long-term commitments of the new management team coupled with a robust business network to support our business initiatives have laid the foundation for the future.
• The current business strategy is to position the Company as an integrated consolidation platform for opportunities based on the managements relationships and experience.

Industry Context

The company's shift towards plant-based industries aligns with the growing market for hemp, CBD, and related products. The company is positioning itself to compete with other plant-based and hemp-related science and consumer product companies trading on the OTC Markets.

Comparison to Industry Standards

• The company's lack of revenue for two consecutive years is a significant deviation from industry standards for operating companies.
• The company's negative working capital and cash balance are concerning and indicate a need for immediate capital infusion.
• The company's strategic shift towards M&A is a common approach for companies in emerging industries, but success depends on effective execution.
• The company's reliance on private placements for funding is typical for small companies on the OTC markets, but it can be dilutive to existing shareholders.
• The company's internal control weaknesses are a concern and need to be addressed to ensure accurate financial reporting.

Management Changes

Legal Proceedings

• The Company may be subject to one or more claims or suits but to our best and current knowledge, there are no current suits at this time.

Related Party Transactions

• The company recorded an impairment loss of $624,289 to impair the prepayment of $145,000 for acquisition of Electrum Partners LLC; of $429,289 deposit on acquisition of Hemp 369; and of $50,000 deposit on acquisition of MetaBioGenix.
• The company paid professional fees of $1,566,940 and $1,567,352 in 2023 and 2022 respectively.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial challenges and potential dilution from future capital raises.
• Employees are impacted by the company's restructuring and limited resources.
• Customers and suppliers are affected by the company's strategic shift and potential changes in operations.
• Creditors face increased risk due to the company's negative working capital and potential inability to meet obligations.

Next Steps

• The company will be working on branding and continuing to build its team in 2024, once it has its new plans funded.
• The company plans to focus on M&A and strategic partnerships to create shareholder value.
• The company will continue to seek funding from other capital sources.

Key Dates

Keywords

plant-based industry, hemp, CBD, consolidation platform, M&A, financial statements, private placement, working capital, internal controls, cannabis